Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis
-
Xometry Appoints Sanjeev Singh Sahni As President Reporting To CEO Randy Altschuler
-
Canadian Large Cap Leaders Split Corp. Announces Intention to Implement a Class A Share Split and Concurrent Preferred Share Private Placement
-
KBS Builders Wins $3.2 Million Contract for Multifamily Construction Project in Maine
-
Unifirst Announces Financial Results for the First Quarter of Fiscal 2025
-
Allegro MicroSystems Redefines Sensing with Launch of New Current Sensor ICs in Compact Packages
-
SiTime Corporation to Announce Fourth Quarter 2024 Financial Results on February 5, 2025
-
APA Corporation Announces Expiration and Final Results of Private Exchange Offers, Tender Offers, and Consent Solicitations and Waiver of Financing Condition
-
The Volcon HF1 secures distribution in UK and Europe
-
Unnatural Products Appoints Abbas Kazimi and Mert Aktar to Board of Directors
-
AerWave Completes First-in-Human Study to Advance Disease-Modifying Ultrasound-Based Therapy for COPD and Asthma
-
Noema Pharma Appoints Michael Samar as Chief Financial Officer
-
InterDigital to Present at 27th Annual Needham Growth Conference
-
SMC Entertainment Closes Acquisition of Boutique Investment Manager, Bateau Asset Management, Providing Entry to Australian and Southeast Asian Financial Services Markets
-
Northwest Registered Agent Launches A Full Suite of Customizable Business Identity Products to Assist New and Aspiring Entrepreneurs
-
HERE Technologies empowers SDV automakers to elevate their brand identity with a fully customizable navigation solution
-
Araris Biotech AG Announces Research Collaboration and Option to License Agreement with Chugai Pharmaceutical Co. to Develop Next-Generation ADCs Using Araris' AraLinQ™ technology
-
Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension
-
Palvella Therapeutics Announces First Patients Dosed in Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations
-
Asia Broadband Corporate Update 2025 – Happy New Year
-
Cogent Biosciences Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
-
CytomX Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
-
Corbus Pharmaceuticals Announces that Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at ASCO GU 2025
-
Windtree Therapeutics Announces New Corporate Strategy Seeking to Identify and Acquire FDA-Approved Revenue Assets While Advancing Its Cardiovascular and Oncology Pipeline
-
COUR Pharmaceuticals Secures FDA Orphan Drug Designation for CNP-104 in Primary Biliary Cholangitis
-
Magna International Inc. Announces Date for Q4 & Year End 2024 Results and 2025 Outlook Webcast
-
Cellebrite Announces Participation in the 27th Annual Needham & Company Growth Conference
-
NV5 Announces New Goal of $1.6 Billion in Revenues by 2028
-
Compass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug Candidate
-
LifeVantage Announces Preliminary Second Quarter Revenue Results and Raises Fiscal 2025 Revenue Guidance
-
Bitterroot Bio Reports Data on Safety and Target Engagement from Phase 1 First-in-Human Study of BRB-002 in Healthy Volunteers
-
ManTech Names Joseph Zuliani Vice President of New Mission Readiness & Enablement Practice
-
Bitdeer Announces December 2024 Production and Operations Update
-
ViGeneron Announces FDA Rare Pediatric Disease Designation for VG901 and DSMB Approval to Advance Dose Escalation in Phase 1b Retinitis Pigmentosa Trial
-
Tokyo Lifestyle Co., Ltd. to Open A New Directly-Operated Store in Hong Kong
-
Infinite Reality Raises $3 Billion; Moves Valuation to $12.25 Billion
-
Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)
-
AXIL Brands Reports Second Quarter Fiscal Year 2025 Financial Results
-
Replimune Announces RP2 Development Program Advances with First Patients Enrolled in Metastatic Uveal Melanoma and Hepatocellular Carcinoma Clinical Trials
-
Sky Quarry Receives Permission to Operate Fractionation Facility at Eagle Springs Refinery Site, Advancing Waste-to-Energy Vision
-
PodcastOne (NASDAQ: PODC) Named 8th Largest US Podcast Publisher by Podtrac for December 2024; Renews Flagship Podcasts with Adam Carolla, Brendan Schaub and Kaitlyn Bristowe
-
UMeWorld Transforms into a Full-Spectrum Wellness Brand with AI-Powered Personalized Solutions
-
Coherus Management to Present at the 43rd Annual J.P. Morgan Healthcare Conference
-
Microbot Medical Announces $8.6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
-
Acres Debuts Layer Library: Combine and Visualize Land Data Seamlessly
-
authID Receives Industry Luminary Classification in The Prism Project’s 2024 Biometric Digital Identity Flagship Report
-
Gain Therapeutics Announces Formation of Clinical Advisory Board to Support Continued Advancement of Lead Drug Candidate GT-02287
-
Magna International Inc. Announces Date for Q4 & Year End 2024 Results and 2025 Outlook Webcast
-
Bitcoin Depot Expands BTM Network Through Partnership with Prominent Texas Convenience Store Chain
-
Cellebrite Announces Participation in the 27th Annual Needham & Company Growth Conference
